Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 2, 2009

Abbott and BioGenex Continue Partnership to Automate FISH Assay Workflow

  • Abbott has extended an agreement to market BioGenex’ Xmatrx® platform for the automation of its FISH product line. Under the terms of the agreement, BioGenex will receive a multiyear minimum volume commitment from Abbott.

    The original technology co-development and distribution agreement and this extension give Abbott customers will have the option to run IHC and FISH on the Xmatrx, and BioGenex customers to run FISH on their system. The Xmatrx will be co-branded and marketed, and both parties to collaborate in aiding adoption of FISH, IHC, and ISH as primary tools in molecular diagnostics and personalized medicine.

    The Xmatrx platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pre-treatment to final cover-slipping, according to BioGenex. It is designed for optimal results with Abbott Molecular AutoFISH™ reagents and FISH technology.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »